MYGN
MYRIAD GENETICS INC
Key Financials
Gross Profit
$576.6M
↓ 1.5%
Net Income
$-365900000
↓ 187.4%
EPS (Diluted)
$-3.95
↓ 180.1%
Total Liabilities
$338.6M
↑ 3.7%
Shareholders' Equity
$368.0M
↓ 47.5%
Revenue
$824.5M
↓ 1.6%
Operating Income
$-387200000
↓ 213.5%
Cash & Equivalents
$149.6M
↑ 46.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/23/2026 | View on SEC |
| 8-K | 6/23/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 144 | 6/8/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MYGN |
| Company Name | MYRIAD GENETICS INC |
| CIK | 899923 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 801-584-3600 |